Answers are grounded in this paper and cite their sources.
Findings show elevated plasma concentrations of ACBP predict lung cancer in smokers, indicating its value as a biomarker for preventive strategies.
These findings independently validate ACBP/DBI as a circulating biomarker of future LC development in at-risk individuals. Clinically, ACBP/DBI quantification could refine risk-adapted lung cancer screening strategies, guiding the frequency of low-dose CT scans and identifying candidates for preventive interventions, including potential ACBP/DBI-neutralizing therapies.
No takes yet. Share an insight, caveat, or question.
Fidelle et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: